We'd all probably agree it's a matter of time, and arguably Synergy has a better therapy than Ironwood. But they would be second to market. So what's a fair valuation for SGYP on an acquisition? It's obviously north of $6, but how high?
interesting, how much do you know about the biopharna industry that you can make such a bold claim?
Pharma is sitting on a dearth of new products in their pipeline. CIC and IBS are multibillion dollar markets with significant unmet need. Linzess' approval has derisked this new class of products, plecanatide has demonstrated competitive efficacy and superior tolerability with a successful Ph III trial and finally, linzess is valued at $2.5+ billion , SGYP about $400 million... nice arbitrage opportunity
bull case for a buyout or global partnership is very very strong.